argenx SE (ARGX) Stock Competitors & Peer Comparison
See (ARGX) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ARGX | $861.97 | -1.63% | 53.4B | 77.57 | $11.08 | N/A |
| VRTX | $478.70 | -0.32% | 120.9B | 25.31 | $18.82 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| REGN | $662.39 | -0.10% | 67.6B | 14.38 | $45.63 | +0.55% |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMDW | $9.13 | +1.90% | 39.9B | -2.20 | -$4.15 | N/A |
| RVMD | $184.53 | +0.31% | 39.3B | -26.16 | -$7.07 | N/A |
| ALNY | $280.18 | -2.74% | 37.6B | 50.68 | $5.55 | N/A |
| ONC | $311.12 | +2.36% | 32.8B | 68.58 | $4.47 | N/A |
| MRNA | $67.16 | +0.22% | 26.8B | -8.27 | -$8.15 | N/A |
Stock Comparison
ARGX vs VRTX Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, VRTX has a market cap of 120.9B. Regarding current trading prices, ARGX is priced at $861.97, while VRTX trades at $478.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas VRTX's P/E ratio is 25.31. In terms of profitability, ARGX's ROE is +0.22%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, ARGX is less volatile compared to VRTX. This indicates potentially lower risk in terms of short-term price fluctuations for ARGX.Check VRTX's competition here
ARGX vs VRNA Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, ARGX is priced at $861.97, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas VRNA's P/E ratio is -102.80. In terms of profitability, ARGX's ROE is +0.22%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, ARGX is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for ARGX.Check VRNA's competition here
ARGX vs REGN Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, REGN has a market cap of 67.6B. Regarding current trading prices, ARGX is priced at $861.97, while REGN trades at $662.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas REGN's P/E ratio is 14.38. In terms of profitability, ARGX's ROE is +0.22%, compared to REGN's ROE of +0.14%. Regarding short-term risk, ARGX is less volatile compared to REGN. This indicates potentially lower risk in terms of short-term price fluctuations for ARGX.Check REGN's competition here
ARGX vs SGEN Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, ARGX is priced at $861.97, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas SGEN's P/E ratio is -57.19. In terms of profitability, ARGX's ROE is +0.22%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, ARGX is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for ARGX.Check SGEN's competition here
ARGX vs RVMDW Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, RVMDW has a market cap of 39.9B. Regarding current trading prices, ARGX is priced at $861.97, while RVMDW trades at $9.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas RVMDW's P/E ratio is -2.20. In terms of profitability, ARGX's ROE is +0.22%, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, ARGX is less volatile compared to RVMDW. This indicates potentially lower risk in terms of short-term price fluctuations for ARGX.Check RVMDW's competition here
ARGX vs RVMD Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, RVMD has a market cap of 39.3B. Regarding current trading prices, ARGX is priced at $861.97, while RVMD trades at $184.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas RVMD's P/E ratio is -26.16. In terms of profitability, ARGX's ROE is +0.22%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, ARGX is less volatile compared to RVMD. This indicates potentially lower risk in terms of short-term price fluctuations for ARGX.Check RVMD's competition here
ARGX vs ALNY Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, ALNY has a market cap of 37.6B. Regarding current trading prices, ARGX is priced at $861.97, while ALNY trades at $280.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas ALNY's P/E ratio is 50.68. In terms of profitability, ARGX's ROE is +0.22%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, ARGX is less volatile compared to ALNY. This indicates potentially lower risk in terms of short-term price fluctuations for ARGX.Check ALNY's competition here
ARGX vs ONC Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, ONC has a market cap of 32.8B. Regarding current trading prices, ARGX is priced at $861.97, while ONC trades at $311.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas ONC's P/E ratio is 68.58. In terms of profitability, ARGX's ROE is +0.22%, compared to ONC's ROE of +0.12%. Regarding short-term risk, ARGX is more volatile compared to ONC. This indicates potentially higher risk in terms of short-term price fluctuations for ARGX.Check ONC's competition here
ARGX vs MRNA Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, MRNA has a market cap of 26.8B. Regarding current trading prices, ARGX is priced at $861.97, while MRNA trades at $67.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas MRNA's P/E ratio is -8.27. In terms of profitability, ARGX's ROE is +0.22%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, ARGX is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for ARGX.Check MRNA's competition here
ARGX vs ROIV Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, ROIV has a market cap of 25.1B. Regarding current trading prices, ARGX is priced at $861.97, while ROIV trades at $35.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas ROIV's P/E ratio is -35.88. In terms of profitability, ARGX's ROE is +0.22%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, ARGX is less volatile compared to ROIV. This indicates potentially lower risk in terms of short-term price fluctuations for ARGX.Check ROIV's competition here
ARGX vs INSM Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, INSM has a market cap of 23.9B. Regarding current trading prices, ARGX is priced at $861.97, while INSM trades at $109.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas INSM's P/E ratio is -19.15. In terms of profitability, ARGX's ROE is +0.22%, compared to INSM's ROE of -1.30%. Regarding short-term risk, ARGX is less volatile compared to INSM. This indicates potentially lower risk in terms of short-term price fluctuations for ARGX.Check INSM's competition here
ARGX vs INCY Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, INCY has a market cap of 23B. Regarding current trading prices, ARGX is priced at $861.97, while INCY trades at $115.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas INCY's P/E ratio is 15.44. In terms of profitability, ARGX's ROE is +0.22%, compared to INCY's ROE of +0.29%. Regarding short-term risk, ARGX is less volatile compared to INCY. This indicates potentially lower risk in terms of short-term price fluctuations for ARGX.Check INCY's competition here
ARGX vs BNTX Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, BNTX has a market cap of 22.9B. Regarding current trading prices, ARGX is priced at $861.97, while BNTX trades at $90.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas BNTX's P/E ratio is -19.57. In terms of profitability, ARGX's ROE is +0.22%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, ARGX is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for ARGX.Check BNTX's competition here
ARGX vs UTHR Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, UTHR has a market cap of 22.4B. Regarding current trading prices, ARGX is priced at $861.97, while UTHR trades at $533.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas UTHR's P/E ratio is 19.44. In terms of profitability, ARGX's ROE is +0.22%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, ARGX is less volatile compared to UTHR. This indicates potentially lower risk in terms of short-term price fluctuations for ARGX.Check UTHR's competition here
ARGX vs BGNE Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, ARGX is priced at $861.97, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas BGNE's P/E ratio is -22.55. In terms of profitability, ARGX's ROE is +0.22%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, ARGX is less volatile compared to BGNE. This indicates potentially lower risk in terms of short-term price fluctuations for ARGX.Check BGNE's competition here
ARGX vs DNA-WT Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, ARGX is priced at $861.97, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, ARGX's ROE is +0.22%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, ARGX is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for ARGX.Check DNA-WT's competition here
ARGX vs GMAB Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, GMAB has a market cap of 17.6B. Regarding current trading prices, ARGX is priced at $861.97, while GMAB trades at $29.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas GMAB's P/E ratio is 20.67. In terms of profitability, ARGX's ROE is +0.22%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, ARGX is less volatile compared to GMAB. This indicates potentially lower risk in terms of short-term price fluctuations for ARGX.Check GMAB's competition here
ARGX vs NBIX Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, NBIX has a market cap of 17.3B. Regarding current trading prices, ARGX is priced at $861.97, while NBIX trades at $171.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas NBIX's P/E ratio is 24.85. In terms of profitability, ARGX's ROE is +0.22%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, ARGX is less volatile compared to NBIX. This indicates potentially lower risk in terms of short-term price fluctuations for ARGX.Check NBIX's competition here
ARGX vs ASND Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, ASND has a market cap of 16.5B. Regarding current trading prices, ARGX is priced at $861.97, while ASND trades at $266.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas ASND's P/E ratio is -109.74. In terms of profitability, ARGX's ROE is +0.22%, compared to ASND's ROE of -56.42%. Regarding short-term risk, ARGX is less volatile compared to ASND. This indicates potentially lower risk in terms of short-term price fluctuations for ARGX.Check ASND's competition here
ARGX vs BBIO Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, BBIO has a market cap of 16.5B. Regarding current trading prices, ARGX is priced at $861.97, while BBIO trades at $82.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas BBIO's P/E ratio is -22.48. In terms of profitability, ARGX's ROE is +0.22%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, ARGX is less volatile compared to BBIO. This indicates potentially lower risk in terms of short-term price fluctuations for ARGX.Check BBIO's competition here
ARGX vs JAZZ Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, JAZZ has a market cap of 15B. Regarding current trading prices, ARGX is priced at $861.97, while JAZZ trades at $239.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas JAZZ's P/E ratio is 18.51. In terms of profitability, ARGX's ROE is +0.22%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, ARGX is less volatile compared to JAZZ. This indicates potentially lower risk in terms of short-term price fluctuations for ARGX.Check JAZZ's competition here
ARGX vs EXEL Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, EXEL has a market cap of 14B. Regarding current trading prices, ARGX is priced at $861.97, while EXEL trades at $55.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas EXEL's P/E ratio is 16.70. In terms of profitability, ARGX's ROE is +0.22%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, ARGX is less volatile compared to EXEL. This indicates potentially lower risk in terms of short-term price fluctuations for ARGX.Check EXEL's competition here
ARGX vs KRTX Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, ARGX is priced at $861.97, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas KRTX's P/E ratio is -28.09. In terms of profitability, ARGX's ROE is +0.22%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, ARGX is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for ARGX.Check KRTX's competition here
ARGX vs MDGL Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, MDGL has a market cap of 12.4B. Regarding current trading prices, ARGX is priced at $861.97, while MDGL trades at $548.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas MDGL's P/E ratio is -41.94. In terms of profitability, ARGX's ROE is +0.22%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, ARGX is less volatile compared to MDGL. This indicates potentially lower risk in terms of short-term price fluctuations for ARGX.Check MDGL's competition here
ARGX vs AXSM Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, AXSM has a market cap of 12.1B. Regarding current trading prices, ARGX is priced at $861.97, while AXSM trades at $235.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas AXSM's P/E ratio is -61.43. In terms of profitability, ARGX's ROE is +0.22%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, ARGX is less volatile compared to AXSM. This indicates potentially lower risk in terms of short-term price fluctuations for ARGX.Check AXSM's competition here
ARGX vs SMMT Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, SMMT has a market cap of 12B. Regarding current trading prices, ARGX is priced at $861.97, while SMMT trades at $15.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas SMMT's P/E ratio is -9.67. In terms of profitability, ARGX's ROE is +0.22%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, ARGX is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for ARGX.Check SMMT's competition here
ARGX vs BMRN Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, BMRN has a market cap of 11.3B. Regarding current trading prices, ARGX is priced at $861.97, while BMRN trades at $58.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas BMRN's P/E ratio is 28.19. In terms of profitability, ARGX's ROE is +0.22%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, ARGX is less volatile compared to BMRN. This indicates potentially lower risk in terms of short-term price fluctuations for ARGX.Check BMRN's competition here
ARGX vs RNAM Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, ARGX is priced at $861.97, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas RNAM's P/E ratio is -17.39. In terms of profitability, ARGX's ROE is +0.22%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, ARGX is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for ARGX.Check RNAM's competition here
ARGX vs TECH Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, TECH has a market cap of 11.2B. Regarding current trading prices, ARGX is priced at $861.97, while TECH trades at $71.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas TECH's P/E ratio is 36.72. In terms of profitability, ARGX's ROE is +0.22%, compared to TECH's ROE of +0.05%. Regarding short-term risk, ARGX is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for ARGX.Check TECH's competition here
ARGX vs CYTK Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, CYTK has a market cap of 10.2B. Regarding current trading prices, ARGX is priced at $861.97, while CYTK trades at $82.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas CYTK's P/E ratio is -14.05. In terms of profitability, ARGX's ROE is +0.22%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, ARGX is less volatile compared to CYTK. This indicates potentially lower risk in terms of short-term price fluctuations for ARGX.Check CYTK's competition here
ARGX vs ARWR Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, ARWR has a market cap of 10.1B. Regarding current trading prices, ARGX is priced at $861.97, while ARWR trades at $71.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas ARWR's P/E ratio is -33.45. In terms of profitability, ARGX's ROE is +0.22%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, ARGX is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for ARGX.Check ARWR's competition here
ARGX vs KRYS Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, KRYS has a market cap of 10B. Regarding current trading prices, ARGX is priced at $861.97, while KRYS trades at $347.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas KRYS's P/E ratio is 45.38. In terms of profitability, ARGX's ROE is +0.22%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, ARGX is less volatile compared to KRYS. This indicates potentially lower risk in terms of short-term price fluctuations for ARGX.Check KRYS's competition here
ARGX vs ABVX Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, ABVX has a market cap of 9.9B. Regarding current trading prices, ARGX is priced at $861.97, while ABVX trades at $135.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas ABVX's P/E ratio is -70.72. In terms of profitability, ARGX's ROE is +0.22%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, ARGX is less volatile compared to ABVX. This indicates potentially lower risk in terms of short-term price fluctuations for ARGX.Check ABVX's competition here
ARGX vs CORT Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, CORT has a market cap of 9.7B. Regarding current trading prices, ARGX is priced at $861.97, while CORT trades at $88.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas CORT's P/E ratio is 258.49. In terms of profitability, ARGX's ROE is +0.22%, compared to CORT's ROE of +0.08%. Regarding short-term risk, ARGX is less volatile compared to CORT. This indicates potentially lower risk in terms of short-term price fluctuations for ARGX.Check CORT's competition here
ARGX vs RXDX Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, ARGX is priced at $861.97, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas RXDX's P/E ratio is -56.47. In terms of profitability, ARGX's ROE is +0.22%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, ARGX is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for ARGX.Check RXDX's competition here
ARGX vs KYMR Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, KYMR has a market cap of 9.2B. Regarding current trading prices, ARGX is priced at $861.97, while KYMR trades at $112.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas KYMR's P/E ratio is -31.75. In terms of profitability, ARGX's ROE is +0.22%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, ARGX is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for ARGX.Check KYMR's competition here
ARGX vs NUVL Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, ARGX is priced at $861.97, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas NUVL's P/E ratio is -21.79. In terms of profitability, ARGX's ROE is +0.22%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, ARGX is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for ARGX.Check NUVL's competition here
ARGX vs IONS Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, IONS has a market cap of 9.1B. Regarding current trading prices, ARGX is priced at $861.97, while IONS trades at $54.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas IONS's P/E ratio is -31.94. In terms of profitability, ARGX's ROE is +0.22%, compared to IONS's ROE of -0.59%. Regarding short-term risk, ARGX is less volatile compared to IONS. This indicates potentially lower risk in terms of short-term price fluctuations for ARGX.Check IONS's competition here
ARGX vs HALO Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, HALO has a market cap of 8.9B. Regarding current trading prices, ARGX is priced at $861.97, while HALO trades at $75.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas HALO's P/E ratio is 16.24. In terms of profitability, ARGX's ROE is +0.22%, compared to HALO's ROE of +1.26%. Regarding short-term risk, ARGX is less volatile compared to HALO. This indicates potentially lower risk in terms of short-term price fluctuations for ARGX.Check HALO's competition here
ARGX vs CRNX Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, CRNX has a market cap of 8.9B. Regarding current trading prices, ARGX is priced at $861.97, while CRNX trades at $83.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas CRNX's P/E ratio is -16.32. In terms of profitability, ARGX's ROE is +0.22%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, ARGX is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for ARGX.Check CRNX's competition here
ARGX vs IMGN Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, ARGX is priced at $861.97, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas IMGN's P/E ratio is -111.55. In terms of profitability, ARGX's ROE is +0.22%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, ARGX is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for ARGX.Check IMGN's competition here
ARGX vs ALKS Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, ALKS has a market cap of 8.6B. Regarding current trading prices, ARGX is priced at $861.97, while ALKS trades at $51.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas ALKS's P/E ratio is 54.32. In terms of profitability, ARGX's ROE is +0.22%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, ARGX is less volatile compared to ALKS. This indicates potentially lower risk in terms of short-term price fluctuations for ARGX.Check ALKS's competition here
ARGX vs PTGX Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, PTGX has a market cap of 8.4B. Regarding current trading prices, ARGX is priced at $861.97, while PTGX trades at $137.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas PTGX's P/E ratio is -72.52. In terms of profitability, ARGX's ROE is +0.22%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, ARGX is less volatile compared to PTGX. This indicates potentially lower risk in terms of short-term price fluctuations for ARGX.Check PTGX's competition here
ARGX vs TGTX Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, TGTX has a market cap of 8.4B. Regarding current trading prices, ARGX is priced at $861.97, while TGTX trades at $55.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas TGTX's P/E ratio is 18.86. In terms of profitability, ARGX's ROE is +0.22%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, ARGX is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for ARGX.Check TGTX's competition here
ARGX vs BPMC Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, ARGX is priced at $861.97, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas BPMC's P/E ratio is -51.58. In terms of profitability, ARGX's ROE is +0.22%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, ARGX is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for ARGX.Check BPMC's competition here
ARGX vs APGE Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, APGE has a market cap of 8.3B. Regarding current trading prices, ARGX is priced at $861.97, while APGE trades at $134.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas APGE's P/E ratio is -30.94. In terms of profitability, ARGX's ROE is +0.22%, compared to APGE's ROE of -0.33%. Regarding short-term risk, ARGX is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for ARGX.Check APGE's competition here
ARGX vs IBRX Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, IBRX has a market cap of 8.3B. Regarding current trading prices, ARGX is priced at $861.97, while IBRX trades at $7.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas IBRX's P/E ratio is -24.62. In terms of profitability, ARGX's ROE is +0.22%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, ARGX is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for ARGX.Check IBRX's competition here
ARGX vs CERE Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, ARGX is priced at $861.97, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas CERE's P/E ratio is -16.47. In terms of profitability, ARGX's ROE is +0.22%, compared to CERE's ROE of -0.72%. Regarding short-term risk, ARGX is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for ARGX.Check CERE's competition here
ARGX vs PCVX Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, PCVX has a market cap of 8.1B. Regarding current trading prices, ARGX is priced at $861.97, while PCVX trades at $56.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas PCVX's P/E ratio is -8.17. In terms of profitability, ARGX's ROE is +0.22%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, ARGX is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for ARGX.Check PCVX's competition here
ARGX vs IMVT Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, IMVT has a market cap of 8B. Regarding current trading prices, ARGX is priced at $861.97, while IMVT trades at $39.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas IMVT's P/E ratio is -14.52. In terms of profitability, ARGX's ROE is +0.22%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, ARGX is less volatile compared to IMVT. This indicates potentially lower risk in terms of short-term price fluctuations for ARGX.Check IMVT's competition here
ARGX vs RYTM Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, RYTM has a market cap of 7.5B. Regarding current trading prices, ARGX is priced at $861.97, while RYTM trades at $109.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas RYTM's P/E ratio is -35.13. In terms of profitability, ARGX's ROE is +0.22%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, ARGX is less volatile compared to RYTM. This indicates potentially lower risk in terms of short-term price fluctuations for ARGX.Check RYTM's competition here
ARGX vs MTSR Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, ARGX is priced at $861.97, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas MTSR's P/E ratio is -23.58. In terms of profitability, ARGX's ROE is +0.22%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, ARGX is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for ARGX.Check MTSR's competition here
ARGX vs PRAX Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, PRAX has a market cap of 6.9B. Regarding current trading prices, ARGX is priced at $861.97, while PRAX trades at $316.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas PRAX's P/E ratio is -24.51. In terms of profitability, ARGX's ROE is +0.22%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, ARGX is less volatile compared to PRAX. This indicates potentially lower risk in terms of short-term price fluctuations for ARGX.Check PRAX's competition here
ARGX vs MRUS Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, ARGX is priced at $861.97, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas MRUS's P/E ratio is -17.05. In terms of profitability, ARGX's ROE is +0.22%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, ARGX is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for ARGX.Check MRUS's competition here
ARGX vs LQDA Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, LQDA has a market cap of 6.8B. Regarding current trading prices, ARGX is priced at $861.97, while LQDA trades at $76.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas LQDA's P/E ratio is 546.36. In terms of profitability, ARGX's ROE is +0.22%, compared to LQDA's ROE of +0.47%. Regarding short-term risk, ARGX is less volatile compared to LQDA. This indicates potentially lower risk in terms of short-term price fluctuations for ARGX.Check LQDA's competition here
ARGX vs ACLX Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, ARGX is priced at $861.97, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas ACLX's P/E ratio is -28.27. In terms of profitability, ARGX's ROE is +0.22%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, ARGX is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for ARGX.Check ACLX's competition here
ARGX vs COGT Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, COGT has a market cap of 6.6B. Regarding current trading prices, ARGX is priced at $861.97, while COGT trades at $39.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas COGT's P/E ratio is -18.25. In terms of profitability, ARGX's ROE is +0.22%, compared to COGT's ROE of -0.83%. Regarding short-term risk, ARGX is less volatile compared to COGT. This indicates potentially lower risk in terms of short-term price fluctuations for ARGX.Check COGT's competition here
ARGX vs RETA Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, ARGX is priced at $861.97, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas RETA's P/E ratio is -66.29. In terms of profitability, ARGX's ROE is +0.22%, compared to RETA's ROE of +0.47%. Regarding short-term risk, ARGX is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for ARGX.Check RETA's competition here
ARGX vs PTCT Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, PTCT has a market cap of 6.5B. Regarding current trading prices, ARGX is priced at $861.97, while PTCT trades at $78.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas PTCT's P/E ratio is -33.50. In terms of profitability, ARGX's ROE is +0.22%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, ARGX is less volatile compared to PTCT. This indicates potentially lower risk in terms of short-term price fluctuations for ARGX.Check PTCT's competition here
ARGX vs SRRK Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, SRRK has a market cap of 6.4B. Regarding current trading prices, ARGX is priced at $861.97, while SRRK trades at $54.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas SRRK's P/E ratio is -14.98. In terms of profitability, ARGX's ROE is +0.22%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, ARGX is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for ARGX.Check SRRK's competition here
ARGX vs CGON Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, CGON has a market cap of 6.3B. Regarding current trading prices, ARGX is priced at $861.97, while CGON trades at $74.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas CGON's P/E ratio is -30.80. In terms of profitability, ARGX's ROE is +0.22%, compared to CGON's ROE of -0.23%. Regarding short-term risk, ARGX is less volatile compared to CGON. This indicates potentially lower risk in terms of short-term price fluctuations for ARGX.Check CGON's competition here
ARGX vs CNTA Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, ARGX is priced at $861.97, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas CNTA's P/E ratio is -22.63. In terms of profitability, ARGX's ROE is +0.22%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, ARGX is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for ARGX.Check CNTA's competition here
ARGX vs MIRM Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, MIRM has a market cap of 6.1B. Regarding current trading prices, ARGX is priced at $861.97, while MIRM trades at $120.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas MIRM's P/E ratio is -8.88. In terms of profitability, ARGX's ROE is +0.22%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, ARGX is less volatile compared to MIRM. This indicates potentially lower risk in terms of short-term price fluctuations for ARGX.Check MIRM's competition here
ARGX vs ERAS Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, ERAS has a market cap of 6.1B. Regarding current trading prices, ARGX is priced at $861.97, while ERAS trades at $21.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas ERAS's P/E ratio is -44.32. In terms of profitability, ARGX's ROE is +0.22%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, ARGX is less volatile compared to ERAS. This indicates potentially lower risk in terms of short-term price fluctuations for ARGX.Check ERAS's competition here
ARGX vs LGND Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, LGND has a market cap of 6B. Regarding current trading prices, ARGX is priced at $861.97, while LGND trades at $296.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas LGND's P/E ratio is 36.09. In terms of profitability, ARGX's ROE is +0.22%, compared to LGND's ROE of +0.16%. Regarding short-term risk, ARGX is less volatile compared to LGND. This indicates potentially lower risk in terms of short-term price fluctuations for ARGX.Check LGND's competition here
ARGX vs SYRE Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, SYRE has a market cap of 6B. Regarding current trading prices, ARGX is priced at $861.97, while SYRE trades at $101.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas SYRE's P/E ratio is -47.57. In terms of profitability, ARGX's ROE is +0.22%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, ARGX is less volatile compared to SYRE. This indicates potentially lower risk in terms of short-term price fluctuations for ARGX.Check SYRE's competition here
ARGX vs BLTE Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, BLTE has a market cap of 5.9B. Regarding current trading prices, ARGX is priced at $861.97, while BLTE trades at $147.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas BLTE's P/E ratio is -78.44. In terms of profitability, ARGX's ROE is +0.22%, compared to BLTE's ROE of -0.18%. Regarding short-term risk, ARGX is less volatile compared to BLTE. This indicates potentially lower risk in terms of short-term price fluctuations for ARGX.Check BLTE's competition here
ARGX vs CDTX Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, ARGX is priced at $861.97, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas CDTX's P/E ratio is -19.77. In terms of profitability, ARGX's ROE is +0.22%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, ARGX is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for ARGX.Check CDTX's competition here
ARGX vs ABCM Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, ARGX is priced at $861.97, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, ARGX's ROE is +0.22%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, ARGX is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for ARGX.Check ABCM's competition here
ARGX vs ISEE Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, ARGX is priced at $861.97, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas ISEE's P/E ratio is -22.44. In terms of profitability, ARGX's ROE is +0.22%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, ARGX is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for ARGX.Check ISEE's competition here
ARGX vs CELC Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, CELC has a market cap of 5.4B. Regarding current trading prices, ARGX is priced at $861.97, while CELC trades at $93.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas CELC's P/E ratio is -28.47. In terms of profitability, ARGX's ROE is +0.22%, compared to CELC's ROE of -2.45%. Regarding short-term risk, ARGX is less volatile compared to CELC. This indicates potentially lower risk in terms of short-term price fluctuations for ARGX.Check CELC's competition here
ARGX vs XENE Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, XENE has a market cap of 5.3B. Regarding current trading prices, ARGX is priced at $861.97, while XENE trades at $67.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas XENE's P/E ratio is -14.32. In terms of profitability, ARGX's ROE is +0.22%, compared to XENE's ROE of -0.49%. Regarding short-term risk, ARGX is less volatile compared to XENE. This indicates potentially lower risk in terms of short-term price fluctuations for ARGX.Check XENE's competition here
ARGX vs TVTX Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, TVTX has a market cap of 5.3B. Regarding current trading prices, ARGX is priced at $861.97, while TVTX trades at $56.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas TVTX's P/E ratio is -259.36. In terms of profitability, ARGX's ROE is +0.22%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, ARGX is less volatile compared to TVTX. This indicates potentially lower risk in terms of short-term price fluctuations for ARGX.Check TVTX's competition here
ARGX vs APLS Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, ARGX is priced at $861.97, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas APLS's P/E ratio is 38.35. In terms of profitability, ARGX's ROE is +0.22%, compared to APLS's ROE of +0.40%. Regarding short-term risk, ARGX is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for ARGX.Check APLS's competition here
ARGX vs DFTX Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, DFTX has a market cap of 5B. Regarding current trading prices, ARGX is priced at $861.97, while DFTX trades at $45.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas DFTX's P/E ratio is N/A. In terms of profitability, ARGX's ROE is +0.22%, compared to DFTX's ROE of -1.02%. Regarding short-term risk, ARGX is less volatile compared to DFTX. This indicates potentially lower risk in terms of short-term price fluctuations for ARGX.Check DFTX's competition here
ARGX vs CRSP Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, CRSP has a market cap of 4.9B. Regarding current trading prices, ARGX is priced at $861.97, while CRSP trades at $50.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas CRSP's P/E ratio is -9.87. In terms of profitability, ARGX's ROE is +0.22%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, ARGX is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for ARGX.Check CRSP's competition here
ARGX vs CAI Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, CAI has a market cap of 4.8B. Regarding current trading prices, ARGX is priced at $861.97, while CAI trades at $17.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas CAI's P/E ratio is -93.23. In terms of profitability, ARGX's ROE is +0.22%, compared to CAI's ROE of +0.06%. Regarding short-term risk, ARGX is less volatile compared to CAI. This indicates potentially lower risk in terms of short-term price fluctuations for ARGX.Check CAI's competition here
ARGX vs TERN Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, ARGX is priced at $861.97, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas TERN's P/E ratio is -51.41. In terms of profitability, ARGX's ROE is +0.22%, compared to TERN's ROE of -0.20%. Regarding short-term risk, ARGX is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for ARGX.Check TERN's competition here
ARGX vs LEGN Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, LEGN has a market cap of 4.7B. Regarding current trading prices, ARGX is priced at $861.97, while LEGN trades at $23.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas LEGN's P/E ratio is -37.75. In terms of profitability, ARGX's ROE is +0.22%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, ARGX is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for ARGX.Check LEGN's competition here
ARGX vs MANE Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, MANE has a market cap of 4.6B. Regarding current trading prices, ARGX is priced at $861.97, while MANE trades at $126.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas MANE's P/E ratio is -34.99. In terms of profitability, ARGX's ROE is +0.22%, compared to MANE's ROE of -0.84%. Regarding short-term risk, ARGX is less volatile compared to MANE. This indicates potentially lower risk in terms of short-term price fluctuations for ARGX.Check MANE's competition here
ARGX vs FOLD Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, ARGX is priced at $861.97, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas FOLD's P/E ratio is -161.00. In terms of profitability, ARGX's ROE is +0.22%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, ARGX is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for ARGX.Check FOLD's competition here
ARGX vs AKRO Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, ARGX is priced at $861.97, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas AKRO's P/E ratio is -14.57. In terms of profitability, ARGX's ROE is +0.22%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, ARGX is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for ARGX.Check AKRO's competition here
ARGX vs ALPN Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, ARGX is priced at $861.97, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas ALPN's P/E ratio is -101.52. In terms of profitability, ARGX's ROE is +0.22%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, ARGX is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for ARGX.Check ALPN's competition here
ARGX vs VKTX Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, VKTX has a market cap of 4.4B. Regarding current trading prices, ARGX is priced at $861.97, while VKTX trades at $37.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas VKTX's P/E ratio is -9.17. In terms of profitability, ARGX's ROE is +0.22%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, ARGX is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for ARGX.Check VKTX's competition here
ARGX vs ACAD Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, ACAD has a market cap of 4.4B. Regarding current trading prices, ARGX is priced at $861.97, while ACAD trades at $25.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas ACAD's P/E ratio is 12.50. In terms of profitability, ARGX's ROE is +0.22%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, ARGX is less volatile compared to ACAD. This indicates potentially lower risk in terms of short-term price fluctuations for ARGX.Check ACAD's competition here
ARGX vs EWTX Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, EWTX has a market cap of 4.3B. Regarding current trading prices, ARGX is priced at $861.97, while EWTX trades at $40.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas EWTX's P/E ratio is -23.93. In terms of profitability, ARGX's ROE is +0.22%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, ARGX is less volatile compared to EWTX. This indicates potentially lower risk in terms of short-term price fluctuations for ARGX.Check EWTX's competition here
ARGX vs OPT Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, ARGX is priced at $861.97, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas OPT's P/E ratio is -1.52. In terms of profitability, ARGX's ROE is +0.22%, compared to OPT's ROE of +1.18%. Regarding short-term risk, ARGX is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for ARGX.Check OPT's competition here
ARGX vs DNTH Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, DNTH has a market cap of 4.2B. Regarding current trading prices, ARGX is priced at $861.97, while DNTH trades at $100.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas DNTH's P/E ratio is -24.54. In terms of profitability, ARGX's ROE is +0.22%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, ARGX is less volatile compared to DNTH. This indicates potentially lower risk in terms of short-term price fluctuations for ARGX.Check DNTH's competition here
ARGX vs NAMSW Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, NAMSW has a market cap of 4.1B. Regarding current trading prices, ARGX is priced at $861.97, while NAMSW trades at $20.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas NAMSW's P/E ratio is -13.76. In terms of profitability, ARGX's ROE is +0.22%, compared to NAMSW's ROE of -0.30%. Regarding short-term risk, ARGX is less volatile compared to NAMSW. This indicates potentially lower risk in terms of short-term price fluctuations for ARGX.Check NAMSW's competition here
ARGX vs MRTX Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, ARGX is priced at $861.97, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas MRTX's P/E ratio is -4.82. In terms of profitability, ARGX's ROE is +0.22%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, ARGX is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for ARGX.Check MRTX's competition here
ARGX vs DYN Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, DYN has a market cap of 3.9B. Regarding current trading prices, ARGX is priced at $861.97, while DYN trades at $23.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas DYN's P/E ratio is -7.39. In terms of profitability, ARGX's ROE is +0.22%, compared to DYN's ROE of -0.58%. Regarding short-term risk, ARGX is less volatile compared to DYN. This indicates potentially lower risk in terms of short-term price fluctuations for ARGX.Check DYN's competition here
ARGX vs NAMS Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, NAMS has a market cap of 3.9B. Regarding current trading prices, ARGX is priced at $861.97, while NAMS trades at $32.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas NAMS's P/E ratio is -20.94. In terms of profitability, ARGX's ROE is +0.22%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, ARGX is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for ARGX.Check NAMS's competition here
ARGX vs CPRX Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, ARGX is priced at $861.97, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas CPRX's P/E ratio is 11.33. In terms of profitability, ARGX's ROE is +0.22%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, ARGX is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for ARGX.Check CPRX's competition here
ARGX vs RYZB Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, ARGX is priced at $861.97, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas RYZB's P/E ratio is -57.86. In terms of profitability, ARGX's ROE is +0.22%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, ARGX is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for ARGX.Check RYZB's competition here
ARGX vs TLX Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, TLX has a market cap of 3.7B. Regarding current trading prices, ARGX is priced at $861.97, while TLX trades at $11.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas TLX's P/E ratio is -598.91. In terms of profitability, ARGX's ROE is +0.22%, compared to TLX's ROE of -0.02%. Regarding short-term risk, ARGX is less volatile compared to TLX. This indicates potentially lower risk in terms of short-term price fluctuations for ARGX.Check TLX's competition here
ARGX vs CBAY Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, ARGX is priced at $861.97, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas CBAY's P/E ratio is -32.81. In terms of profitability, ARGX's ROE is +0.22%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, ARGX is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for ARGX.Check CBAY's competition here
ARGX vs ELVN Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, ELVN has a market cap of 3.7B. Regarding current trading prices, ARGX is priced at $861.97, while ELVN trades at $52.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas ELVN's P/E ratio is -30.98. In terms of profitability, ARGX's ROE is +0.22%, compared to ELVN's ROE of -0.21%. Regarding short-term risk, ARGX is less volatile compared to ELVN. This indicates potentially lower risk in terms of short-term price fluctuations for ARGX.Check ELVN's competition here
ARGX vs TNGX Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, TNGX has a market cap of 3.7B. Regarding current trading prices, ARGX is priced at $861.97, while TNGX trades at $30.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas TNGX's P/E ratio is -35.72. In terms of profitability, ARGX's ROE is +0.22%, compared to TNGX's ROE of -0.42%. Regarding short-term risk, ARGX is less volatile compared to TNGX. This indicates potentially lower risk in terms of short-term price fluctuations for ARGX.Check TNGX's competition here
ARGX vs DNLI Comparison July 2026
ARGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 53.4B. In comparison, DNLI has a market cap of 3.6B. Regarding current trading prices, ARGX is priced at $861.97, while DNLI trades at $22.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 77.57, whereas DNLI's P/E ratio is -7.86. In terms of profitability, ARGX's ROE is +0.22%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, ARGX is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for ARGX.Check DNLI's competition here